Profound Medical Corp. (PROF) closed at $7.68 on November 10, 2026, up 4.6% from the previous close, on volume of 228,684 shares (30-day average 299,158).
Data as of November 10, 2026.
Profound Medical to Present at Stifel Healthcare Conference
TipRanks (Mon, 9-Nov 8:13 AM ET)
Profound Medical to Participate in the Stifel 2026 Healthcare Conference
Globe Newswire (Mon, 9-Nov 7:45 AM ET)
Profound Medical Earnings Call Highlights Growth and Risks
TipRanks (Sun, 8-Nov 7:16 PM ET)
Profound Medical (PRN) Gets a Buy from Stifel Nicolaus
TipRanks (Fri, 6-Nov 2:39 PM ET)
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Globe Newswire (Fri, 30-Oct 8:00 AM ET)
Emmy-Award Winning Television Host Montel Williams to Join Next 'Let's Huddle' Webinar
Globe Newswire (Thu, 22-Oct 4:15 PM ET)
Globe Newswire (Wed, 14-Oct 7:30 AM ET)
Globe Newswire (Fri, 9-Oct 7:45 AM ET)
PROF jumps as preliminary Q3 revenue is pegged 45%–47% above Bloomberg consensus
Market Chameleon (Thu, 8-Oct 6:58 AM ET)
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Profound Medical Corp. trades on the NASDAQ stock market under the symbol PROF.
As of November 11, 2026, PROF stock price climbed to $7.72 with 17,888 million shares trading.
PROF has a beta of 1.28, meaning it tends to be more sensitive to market movements. PROF has a correlation of 0.05 to the broad based SPY ETF.
PROF has a market cap of $282.76 million. This is considered a Small Cap stock.
Last quarter Profound Medical Corp. reported $10 million in Revenue and -$.21 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.02.
In the last 3 years, PROF traded as high as $11.69 and as low as $3.76.
The top ETF exchange traded funds that PROF belongs to (by Net Assets): QQQS, DFIC.
PROF has outperformed the market in the last year with a price return of +28.9% while the SPY ETF gained +12.4%. PROF has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.2% and +36.8%, respectively, while the SPY returned -1.7% and -1.5%, respectively.
PROF support price is $7.32 and resistance is $8.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PROF shares will trade within this expected range on the day.
